Get the Stockscreener App
4.49
2.05%
0.09
After Hours:
4.49
Trisalus Life Sciences Inc stock is traded at $4.49, with a volume of 163.18K.
It is up +2.05% in the last 24 hours and up +10.05% over the past month.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
See More
Previous Close:
$4.40
Open:
$4.39
24h Volume:
163.18K
Relative Volume:
0.91
Market Cap:
$275.75M
Revenue:
$45.15M
Net Income/Loss:
$-39.23M
P/E Ratio:
-2.4549
EPS:
-1.829
Net Cash Flow:
$-18.93M
1W Performance:
+8.45%
1M Performance:
+10.05%
6M Performance:
-1.10%
1Y Performance:
-18.66%
1-Day Range:
$4.325
$4.50
1-Week Range:
$4.038
$4.575
52-Week Range:
$3.42
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Name
Trisalus Life Sciences Inc
Sector
Industry
Phone
415 336 8917
Address
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
4.49 | 270.22M | 45.15M | -39.23M | -18.93M | -1.829 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Lake Street | Buy |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-11-24 | Initiated | ROTH MKM | Buy |
| Oct-25-24 | Initiated | Northland Capital | Outperform |
| Sep-16-24 | Initiated | Oppenheimer | Outperform |
| May-30-24 | Initiated | Canaccord Genuity | Buy |
View All
Trisalus Life Sciences Inc Stock (TLSI) Latest News
Bull Run: Will TriSalus Life Sciences Inc benefit from rate cuts2026 Retail & Weekly Hot Stock Watchlists - baoquankhu1.vn
Sentiment Recap: Is TriSalus Life Sciences Inc Equity Warrant a strong growth stock2026 Earnings Impact & Consistent Profit Alerts - baoquankhu1.vn
TLSI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Volume Summary: Is TriSalus Life Sciences Inc Equity Warrants growth already priced in2026 Price Swings & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Aug Swings: Is TriSalus Life Sciences Inc stock a value trap2026 Risk Factors & Reliable Price Breakout Signals - baoquankhu1.vn
TriSalus Life Sciences to Present New Data at 2026 Radiology Conference - National Today
TriSalus to present drug delivery data at radiology meeting By Investing.com - Investing.com South Africa
TriSalus to present drug delivery data at radiology meeting - Investing.com
TriSalus brings liver and uterine treatment data to SIR 2026 - Stock Titan
TriSalus to elevate director to chief medical officer role - BizWest
Trisalus Life Sciences, Inc. Appoints Richard Marshall, M.D., as Chief Medical Officer, Effective June 29, 2026 - marketscreener.com
TriSalus names Richard Marshall as chief medical officer By Investing.com - Investing.com India
TriSalus Life Sciences, Inc. Files Form 8-K on April 1, 2026 Announcing Press Release and Company Information - Minichart
TriSalus names Richard Marshall as chief medical officer - Investing.com
TriSalus Life Sciences Names Richard Marshall Chief Medical Officer - TipRanks
Transcend Appoints Elizabeth Jackson as Senior Vice President of Marketing - Weekly Voice
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer - Weekly Voice
Oncology company TriSalus taps interventional radiologist as medical chief - Stock Titan
TriSalus Life Sciences (TLSI) taps Richard Marshall, M.D., as Chief Medical Officer - Stock Titan
TLSI Technical Analysis & Stock Price Forecast - Intellectia AI
Laramie’s Unlocked Labs fights kidney stones with enzymes - BizWest
Director converts 100,000 TriSalus (TLSI) preferred shares into common - Stock Titan
TLSI Should I Buy - Intellectia AI
Revenue Check: Why is TriSalus Life Sciences Inc stock going up2026 Key Highlights & Entry Point Confirmation Signals - baoquankhu1.vn
Aug PreEarnings: Is TriSalus Life Sciences Inc Equity Warrant in a long term uptrend2026 Market Mood & Technical Buy Zone Confirmation - baoquankhu1.vn
Executive pay and board elections at TriSalus (TLSI) 2026 virtual shareholder meeting - Stock Titan
Aug PreEarnings: Is TriSalus Life Sciences Inc Equity Warrants growth already priced inDip Buying & Weekly Top Performers Watchlists - baoquankhu1.vn
Published on: 2026-03-26 07:22:01 - baoquankhu1.vn
Momentum Shift: Does TriSalus Life Sciences Inc have pricing power2026 Top Gainers & Technical Confirmation Alerts - baoquankhu1.vn
What is Northland Securities' Estimate for TLSI Q1 Earnings? - MarketBeat
TLSI SEC FilingsTriSalus Life Sciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Selling: TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $17,998.54 in Stock - Defense World
Insider Selling: TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $61,384.40 in Stock - Defense World
Weekly Earnings: Can TriSalus Life Sciences Inc Equity Warrant keep up with sector leadersMarket Risk Analysis & Fast Exit and Entry Trade Guides - baoquankhu1.vn
TriSalus Life Sciences launches proposed public stock offering - MSN
Aug Movers: Is TriSalus Life Sciences Inc Equity Warrant a top pick in the sector2026 Price Targets & Community Consensus Trade Signals - baoquankhu1.vn
RSI Check: Is TriSalus Life Sciences Inc Equity Warrant forming a bullish divergenceMarket Volume Summary & AI Powered Market Trend Analysis - baoquankhu1.vn
Top TriSalus Executives Make Major Moves With Insider Stock Sales - TipRanks
TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $17,998.54 in Stock - MarketBeat
TriSalus Life Sciences (NASDAQ:TLSI) CEO Sells $61,384.40 in Stock - MarketBeat
Szela, CEO of TriSalus, sells $79k in TLSI stock By Investing.com - Investing.com India
Szela, CEO of TriSalus, sells $79k in TLSI stock - Investing.com
TriSalus Life Sciences (TLSI) chief regulatory officer sells $14509 in stock - Investing.com
Trisalus Life Sciences’ CCO Marshak sells $14k in TLSI stock - Investing.com UK
Devlin Jodi, TriSalus Life Sciences chief, sells $13k in TLSI stock - Investing.com India
TriSalus Life Sciences chief of research Cox sells $13k in TLSI stock - Investing.com
TriSalus (TLSI) executive sells 3,207 shares to satisfy RSU tax withholding - Stock Titan
TriSalus (TLSI) Chief of Research has 3,184 shares sold for tax withholding - Stock Titan
TriSalus (TLSI) CCO logs small tax-related share disposals, retains over 110K shares - Stock Titan
TriSalus Life Sciences (TLSI) CRO sells shares for taxes - Stock Titan
TriSalus (TLSI) CEO Szela disposes 20,302 shares for tax withholding - Stock Titan
Trisalus Life Sciences Inc Stock (TLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Trisalus Life Sciences Inc Stock (TLSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Devlin Jodi | Chief of Clinical Operations |
Mar 11 '26 |
Sale |
4.13 |
1,162 |
4,799 |
99,409 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 16 '26 |
Sale |
4.12 |
273 |
1,125 |
97,364 |
| Cox Bryan F. | Chief of Research |
Mar 12 '26 |
Sale |
4.09 |
1,467 |
6,000 |
163,994 |
| Cox Bryan F. | Chief of Research |
Mar 11 '26 |
Sale |
4.13 |
1,138 |
4,700 |
165,461 |
| Cox Bryan F. | Chief of Research |
Mar 16 '26 |
Sale |
4.12 |
579 |
2,385 |
163,415 |
| Marshak Richard | Chief Commercial Officer |
Mar 12 '26 |
Sale |
4.09 |
1,589 |
6,499 |
110,816 |
| Marshak Richard | Chief Commercial Officer |
Mar 11 '26 |
Sale |
4.13 |
1,449 |
5,984 |
112,405 |
| Marshak Richard | Chief Commercial Officer |
Mar 16 '26 |
Sale |
4.12 |
419 |
1,726 |
110,397 |
| Stevens Jennifer | Chief Regulatory Officer |
Mar 12 '26 |
Sale |
4.09 |
1,552 |
6,348 |
124,884 |
| Stevens Jennifer | Chief Regulatory Officer |
Mar 11 '26 |
Sale |
4.13 |
1,204 |
4,973 |
126,436 |
2.40%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):